Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation.

摘要: Background and Aim:  The majority of patients with post-transplantation recurrence hepatocellular carcinoma (HCC) have extrahepatic metastases multifocal lesions. Therefore, they few treatment options may not be amenable for local therapy. safety efficacy palliative chemotherapy in this population has been reported. Methods:  We retrospectively analyzed 24 who received recurrent HCC after liver transplantation between January 2000 December 2006 at the Seoul National University Hospital. Results:  mean age was 55 years (range 42–70 years). most commonly used chemotherapeutic regimens were 5-fluorouracil (5-FU)/cisplatin (n = 9), which followed by capecitabine/cisplatin (n = 4), 5-FU/mitomycin (n = 3), 5-FU/oxaliplatin (n = 1), S-1 capecitabine gemcitabine/oxaliplatin gemcitabine/cisplatin 5-FU/interferon (n = 1) sorafenib (n = 2). Grade 3/4 hematological toxicity neutropenia (29.1%), thrombocytopenia (20.9%) anemia (20.9%). There no cases neutropenic fever or bleeding events. non-hematological included elevation transaminase (8.4%) jaundice (16.7%). No patient showed an objective response four (16.7%) demonstrated stable disease. median time to progression 7.0 weeks (95% CI 5.8–8.2) overall survival 16.6 weeks 10.1–23.1). Conclusion:  Palliative can delivered tolerable toxicity. However, date is satisfactory. more effective systemic needed group patients.